Business Wire

PA-WESTINGHOUSE-ELECTRIC

Share
Westinghouse Organizes VVER Fuel Forum with Customers

Westinghouse organized the 5th annual VVER Fuel Forum in Bratislava with representatives from six utilities. The forum, hosted by Slovenské elektrárne, provided the opportunity to share experiences and best practices with VVER-1000 and VVER-440 fuel deployment in operating reactors.

Westinghouse offered detailed briefings on fuel licensing, NOVA E-6 design enhancements, fabrication plant upgrades, delivery and operations.

As the leader of the European Union-funded APIS project (Accelerated Program for Implementation of secure VVER fuel Supply), Westinghouse also presented additional information on next-generation fuel design development and a harmonized approach for VVER fuel licensing.

“We are pleased to host so many colleagues in Bratislava to discuss the critical topic of fuel diversification,” said Branislav Strýček, Chairman of the Board of the Board of Directors and General Director of Slovenské elektrárne. “We are currently going through the preparation of the documentation in Slovakia for new VVER-440 fuel and expect to finish the licensing process by 2026-2027. We are looking forward to achieving diversification of fuel sources as we expand the lifetime operations of our nuclear plants.”

“In Ukraine, we started the licensing process for the Westinghouse VVER-440 fuel in 2022 and, thanks to great cooperation, we successfully completed it within 1.5 years. We received the first fuel load for Rivne unit 2 last September, ahead of the originally planned schedule. Our two units will be operating later this year with the new fuel, which has been performing well after six months," said Olexandr Depenchuk, Director for Nuclear and Radiation Safety of Energoatom. “The joint efforts of Energoatom and Westinghouse have enabled us to end our dependence on Russian fuel.”

“We recommend expediting the ongoing fuel diversification efforts in the context of the REPowerEU Plan launched in May 2022 and the global energy disruption caused by Russia’s invasion of Ukraine,” said Stefano Ciccarello, Acting Director General of the Euratom Supply Agency.

In Finland, Fortum is pursuing mechanical operating experiences with the new fuel type, after a test assembly manufactured by Westinghouse was loaded into the Loviisa-2 reactor last year. “The changes done in the design of the VVER-440 fuel we originally used in Loviisa in the early 2000s improved the fuel behavior and performance. We are currently reviewing the licensing and manufacturing documentation of the first new fuel deliveries and expect this work to be ready this summer,” said Iiro-Ville Lehtinen, Fortum Project Manager.

“Westinghouse will deliver the first batch of VVER-440 fuel assemblies to the Dukovany nuclear power plant at the end of this year. The deliveries for Temelín will follow a few months after Dukovany, as mutually agreed based on the refueling schedule,” said Rostislav Štaubr, Head of Nuclear Fuel Procurement of CEZ.

“We really appreciate our collaboration with Westinghouse,” said Svilena Nikolova, Head of Legal and Commercial Department of Kozloduy Nuclear Power Plant. “The diversification that has been obtained in terms of nuclear fuel supply is of great importance for the power plant. As Kozloduy celebrates its 50th anniversary this year, we will also receive the first load of new VVER-1000 fuel from Westinghouse for our unit 5.”

“We are delighted to share the achievements of this key program to ensure energy security and supply diversification for our customers in the region,” said Tarik Choho, Westinghouse President of Nuclear Fuel. “There were many great achievements in the past years and still a lot of work ahead of us. As the only European VVER fuel manufacturer, we are committed to delivering what is required by our customers.”

Westinghouse is a leading supplier of nuclear fuel, providing a uniquely diversified portfolio in the industry across nuclear reactor types, including PWR, BWR, AGR and VVER. Through our world-class manufacturing facilities in Sweden, the U.K. and the U.S., we focus on delivering innovative fuel technologies to meet our customers’ needs for lower fuel cycle costs, increased operational flexibility and efficiency, diversity of supply and accident-tolerant products. Learn more about our advanced fuel capabilities and how they relate to different reactors around the world: Westinghouse Nuclear > Nuclear Fuel.

Westinghouse Electric Company is shaping the future of carbon-free energy by providing safe, innovative nuclear technologies to utilities globally. Westinghouse supplied the world’s first commercial pressurized water reactor in 1957 and the company’s technology is the basis for nearly one-half of the world's operating nuclear plants. Over 135 years of innovation make Westinghouse the preferred partner for advanced technologies covering the complete nuclear energy life cycle. For more information, visit www.westinghousenuclear.com and follow us on Facebook, LinkedIn and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240222283969/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye